Search Results
Your search for Alok A. Khorana, MD matches 23 pages
Showing 1 - 23Cleveland Clinic Cancer Center Oncologists Earn National Recognition as Institution Expands Staff
Cleveland Clinic Cancer Center recently announced news about the following physicians, including the appointment of four new staff members: Shilpa Gupta, MD, received a 2-year, $573,850 grant from the Department of Defense to study biomarkers of response and resistance to immunotherapy and to apply ...
Alok A. Khorana, MD, and Hedy L. Kindler, MD, on Metastatic Pancreatic Cancer: POLO Trial on Olaparib as Maintenance Therapy
Alok A. Khorana, MD, of the Cleveland Clinic, and Hedy L. Kindler, MD, of The University of Chicago, discuss phase III findings on olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with metastatic pancreatic cancer and a germline BRCA mutation (Abstract...
ASCO Clinical Opinion Recommends Germline Testing for All Patients With Pancreatic Cancer
The recently released ASCO Clinical Practice Provisional Clinical Opinion on Evaluating Susceptibility to Pancreatic Cancer highlights the importance of emerging data indicating a relatively high rate of germline mutations in pancreatic cancer.1 Recent studies have demonstrated that up to 1 in 10...
Direct Oral Anticoagulants Show Reduced Risk of Venous Thromboembolism in Patients With Cancer
Results of a recent study suggest that direct oral anticoagulants can reduce the risk of thromboembolism in patients with cancer who are starting a new systemic therapy regimen, without significantly increasing the risk of major bleeding. Data presented at the 2018 ASH Annual Meeting &...
Primary Prophylaxis With a Direct Oral Anticoagulation Agent Reduces Venous Thromboembolism Rate in Ambulatory Patients With Cancer
LATE-BREAKING results from the large, randomized, placebo-controlled CASSINI trial showed that primary prophylaxis with the direct oral anticoagulation agent rivaroxaban reduced the incidence of venous thromboembolism (VTE) as well as VTE-related deaths in high-risk patients with cancer who were...
Alok A. Khorana, MD, on Reducing VTE Associated With Systemic Cancer Therapy: Results From the CASSINI Trial
Alok A. Khorana, MD, of the Cleveland Clinic, discusses study findings on rivaroxaban thromboprophylaxis in high-risk ambulatory patients, which showed a reduction in venous thromboembolism and related death (Abstract LBA1).
ASH 2018: CASSINI Trial: Rivaroxaban Thromboprophylaxis for VTE Prevention in Patients With Cancer
A new study suggests taking a direct oral anticoagulant (DOAC) can reduce the risk of harmful blood clots in patients undergoing cancer treatments, without substantially increasing the risk of bleeding problems. Findings from the CASSINI trial were presented by Khorana et al at the 2018 American...
Cleveland Clinic Researchers Receive NIH Grant to Study Cancer-Associated Thrombosis
THE NATIONAL Heart, Lung, and Blood Institute has awarded a $4.7 million grant to the Cleveland Clinic to study the prevention of cancer-associated thrombosis. The 5-year grant supports the creation of a new risk assessment tool to better predict patients with cancer who have a higher probability...
2018 Fellows of the American Society of Clinical Oncology (FASCO) Recognized During Annual Meeting in Chicago
The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly, the individuals at risk for, or with...
ASCO Honors Leaders in Cancer Care With 2018 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked to transform...
Alok A. Khorana, MD, on The Costs of VTE in Cancer Patients: Expert Perspective
Alok A. Khorana, MD, of the Cleveland Clinic, discusses the prevalence of venous thromboembolism in cancer patients treated at U. S. emergency departments and associated costs, mortality, and hospital admissions in the United States (Abstract 219).
Potential Biomarker of Recurrent Venous Thromboembolism in Patients Receiving Anticoagulants
In a biomarker analysis of the CATCH trial reported in the Journal of Clinical Oncology, Alok A. Khorana, MD, of the Cleveland Clinic, and colleagues found that elevated circulating tissue factor levels were associated with an increased risk of recurrent venous thromboembolism in cancer patients on ...
Potential Biomarker of Recurrent Venous Thromboembolism in Cancer Patients Receiving Anticoagulant Therapy
In a biomarker analysis of the CATCH trial reported in the Journal of Clinical Oncology, Khorana et al found that elevated circulating tissue factor levels were associated with an increased risk of recurrent venous thromboembolism in cancer patients on anticoagulant therapy. CATCH was a randomized ...
ASCO Guideline on Potentially Curable Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Alok A. Khorana, MD, of Cleveland Clinic, and colleagues, ASCO has released a clinical practice guideline on the treatment of potentially curable pancreatic cancer.1 The recommendations are based on an expert panel systematic review of the...
ASCO Releases Clinical Practice Guideline on Treatment of Potentially Curable Pancreatic Cancer
ASCO has released a clinical practice guideline on the treatment of potentially curable pancreatic cancer, as reported by Alok A. Khorana, MD, of Cleveland Clinic, and colleagues, in the Journal of Clinical Oncology. The recommendations are based on expert panel systematic review of the literature...
Anticoagulation in Patients With Cancer: Understanding the Complexities of Prophylaxis and Management
Venous thromboembolic events are more prevalent in patients with cancer than in persons without it. Cancer is associated with a high rate of venous thromboembolism recurrence, bleeding, requirement for long-term anticoagulation, and reduced quality of life. Moreover, thrombosis is the second most...
SIDEBAR: Expect Questions from Your Patients
The current lack of awareness about the high risk of venous thromboembolism (VTE) among people being treated for cancer as outpatients means “there’s a great role for provider education,” Alok Khorana, MD, told The ASCO Post. Here are Dr. Khorana’s answers to some likely questions from patients....
SIDEBAR: Clinical Trials of VTE Prophylaxis for Outpatients
Several studies are investigating low-molecular-weight heparins to reduce the risk of venous thromboembolism (VTE) among patients with cancer. “I enrolled patients in SAVE-ONCO,” Alok Khorana, MD, said, “but that trial used drug called semuloparin, which is not currently available in the United...
Outpatients Need to Be Aware of High Risk of Developing Venous Thromboembolism
Most patients who develop venous thromboembolisms (VTE) while being treated for cancer, do so as outpatients, according to results of a retrospective, observational study comparing the incidence of VTE among inpatients and outpatients with cancer. Yet many outpatients do not even realize that they...
SIDEBAR: Venous Thromboembolism Expert Panel
Gary H. Lyman, MD, MPH, FRCP (Edin), Co-Chair, Duke University Medical Center Anna Falanga, MD, Co-Chair, Ospedali Riuiniti Bergamo, Italy Daniel Clarke-Pearson, MD, University of North Carolina Christopher Flowers, MD, MS, Winship Cancer Institute Charles W. Francis, MD, University of...
Understanding the Impact of Results From CALGB/ SWOG 80405 and Other New Data in Colorectal Cancer
The Cancer and Leukemia Group B (CALGB)/Southwest Oncology Group (SWOG) 80405 trial, presented during the Plenary Session at this year’s ASCO Annual Meeting, demonstrated that cetuximab (Erbitux) and bevacizumab (Avastin) confer similar benefits as first-line treatment with chemotherapy for KRAS...
Two Factors Predict for Recurrent Venous Thromboembolism in Patients With Cancer
Patients with cancer who develop venous thromboembolism are at high risk of such obstructive disease recurring despite adequate anticoagulation. A prespecified analysis of the CATCH trial identified two major predictors of recurrence: venous compression by the tumor and a diagnosis of hepatobiliary ...
Alok A. Khorana, MD, on Preventing Venous Thromboembolism
Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).
